Trial Profile
Early-Phase Study to Assess Tumor Pharmacokinetics and Efficacy of the CDK4/6 Inhibitor Ribociclib (LEE011) in Patients With Recurrent Glioblastoma or Anaplastic Glioma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ribociclib (Primary)
- Indications Glioblastoma; Glioma
- Focus Therapeutic Use
- 05 Jun 2018 Planned End Date changed from 1 Jan 2018 to 1 Jan 2020.
- 05 Jun 2018 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2019.
- 05 Jun 2018 Status changed from recruiting to active, no longer recruiting.